Search

Your search keyword '"Ligand Pharmaceuticals Inc."' showing total 357 results
Start Over Descriptor "Ligand Pharmaceuticals Inc." Topic pharmaceuticals and cosmetics industries
357 results on '"Ligand Pharmaceuticals Inc."'

1. Verona Pharma gets US FDA approval for Ohtuvayre for maintenance treatment of COPD in adult patients in more than 20 years

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Respiratory agents, Lung diseases, Obstructive -- Drug therapy, Drug approval, Pharmaceutical industry, Pharmaceuticals and cosmetics industries
Abstract

Ligand Pharmaceuticals Inc, a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines, announced its partner Verona Pharma plc has received approval from the US Food [...]

Published
2024

3. Ligand Pharmaceuticals Inc. Files SEC Form SC 13G/A, Statement of Beneficial Ownership By Certain Investors: (Nov. 1, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 NOV 20 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

4. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Sept. 18, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

5. Ligand Pharmaceuticals Inc. Files SEC Form S-8, Securities To Be Offered To Employees in Employee Benefit Plans: (Jul. 9, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Employee benefits, Pharmaceutical industry, Employee benefits, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 JUL 24 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

6. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jul. 2, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

7. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jun. 25, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 JUL 10 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

8. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jun. 18, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

9. Ligand Pharmaceuticals Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material: (Jun. 3, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Securities law, Proxy, Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 JUN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

10. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (May 17, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 JUN 5 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

11. Ligand Pharmaceuticals Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material: (May 9, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Securities law, Proxy, Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 MAY 29 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

12. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Apr. 26, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 MAY 15 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

13. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Mar. 27, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

14. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Mar. 7, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 MAR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

15. Ligand Pharmaceuticals Inc. Files SEC Form S-8, Securities To Be Offered To Employees in Employee Benefit Plans: (Mar. 1, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Employee benefits, Pharmaceutical industry, Employee benefits, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

16. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Mar. 6, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

17. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Feb. 29, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

18. Ligand Pharmaceuticals Inc. Files SEC Form 10-K, Annual Report [Section 13 And 15(D), Not S-k Item 405]: (Feb. 29, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

19. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Feb. 16, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 MAR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

20. Ligand Pharmaceuticals Inc. Files SEC Form SC 13G/A, Statement of Acquisition of Beneficial Ownership By Individuals: (Feb. 13, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

21. Ligand Pharmaceuticals Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals: (Feb. 12, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

22. Ligand Pharmaceuticals Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals: (Feb. 14, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

23. Ligand Pharmaceuticals Inc. Files SEC Form SC 13G/A, Statement of Acquisition of Beneficial Ownership By Individuals: (Jan. 22, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 FEB 7 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

24. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jan. 4, 2024)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2024 JAN 24 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2024

25. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Dec. 6, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 DEC 20 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

26. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Oct. 3, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 OCT 18 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

27. Ligand Pharmaceuticals Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities: (Sept. 25, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 OCT 11 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

28. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jul. 10, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JUL 26 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

29. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jun. 21, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JUL 5 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

30. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jun. 13, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JUN 28 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

31. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (May 18, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JUN 7 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

32. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (May 12, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAY 31 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

33. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (May 10, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAY 24 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

34. Ligand Pharmaceuticals Inc. Files SEC Form DEF 14A, Other Definitive Proxy Statements: (Apr. 20, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAY 10 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

35. Ligand Pharmaceuticals Inc. Files SEC Form CT ORDER, Confidential Treatment Order: (Apr. 26, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAY 10 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

36. Ligand Pharmaceuticals Inc. Files SEC Form ARS, Annual Report To Security Holders: (Apr. 20, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAY 10 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

37. Ligand Pharmaceuticals Inc. Files SEC Form SC 13D/A, General Statement of Acquisition of Beneficial Ownership: (Mar. 30, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 APR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

38. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Mar. 28, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 APR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

39. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Feb. 27, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

40. Ligand Pharmaceuticals Inc. Files SEC Form 10-K, Annual Report [Section 13 And 15(D), Not S-k Item 405]: (Feb. 28, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

41. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Feb. 17, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

42. Ligand Pharmaceuticals Inc. Files SEC Form SC 13G/A, Statement of Acquisition of Beneficial Ownership By Individuals: (Jan. 26, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 FEB 15 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

43. Ligand Pharmaceuticals Inc. Files SEC Form SC 13G/A, Statement of Acquisition of Beneficial Ownership By Individuals: (Jan. 20, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 FEB 8 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

44. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jan. 4, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JAN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

45. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Dec. 30, 2022)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JAN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

46. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Dec. 27, 2022)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

47. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Dec. 14, 2022)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2022 DEC 28 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2022

48. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Dec. 6, 2022)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2022 DEC 21 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2022

49. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Dec. 1, 2022)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2022 DEC 21 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2022

50. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Nov. 21, 2022)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2022 DEC 7 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results